-
Purposerecombinant AAV vector packaging single-stranded Firefly Luciferase under the CAG promoter (includes WPRE element)
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 83281 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepAAV with CAG promoter
- Backbone size w/o insert (bp) 4721
- Total vector size (bp) 6374
-
Vector typeMammalian Expression, AAV
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Growth instructionsNeed to check for integrity of ITRs by restriction digest with AhdI, also with XmaI.
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameFirefly Luciferase
-
SpeciesPhotinus pyralis (Firefly)
-
Insert Size (bp)1653
- Promoter CAG
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site BamH1 (not destroyed)
- 3′ cloning site EcoR1 (not destroyed)
- 5′ sequencing primer GTTATTGTGCTGTCTCATC
- 3′ sequencing primer CATTAAAGCAGCGTATCC (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
-
A portion of this plasmid was derived from a plasmid made byAAV backbone as well as CAG promoter and WPRE sequences were obtained from Addgene plasmid #37825, sequences for the FLuc gene were obtained from Addgene plasmid #21375
-
Articles Citing this Plasmid
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pAAV-CAG-FLuc was a gift from Mark Kay (Addgene plasmid # 83281 ; http://n2t.net/addgene:83281 ; RRID:Addgene_83281) -
For your References section:
Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors. Pekrun K, De Alencastro G, Luo QJ, Liu J, Kim Y, Nygaard S, Galivo F, Zhang F, Song R, Tiffany MR, Xu J, Hebrok M, Grompe M, Kay MA. JCI Insight. 2019 Nov 14;4(22). pii: 131610. doi: 10.1172/jci.insight.131610. 10.1172/jci.insight.131610 PubMed 31723052